Monitoring molecular response in chronic myeloid leukemia

Jorge Cortes, Alfonso Quintás-Cardama, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a reliance on molecular monitoring to assess residual leukemic disease. The prognostic significance between molecular responses and duration of complete cytogenetic response, progression-free survival, and event-free survival is described herein. A discussion of the concept of complete molecular response is also provided, and the potential for imatinib treatment discontinuation is evaluated. The implications of rising BCR-ABL1 transcript levels and caveats of molecular monitoring are also described.

Original languageEnglish (US)
Pages (from-to)1113-1122
Number of pages10
JournalCancer
Volume117
Issue number6
DOIs
StatePublished - Mar 15 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Protein-Tyrosine Kinases
Disease-Free Survival
Therapeutics

Keywords

  • BCR-ABL
  • chronic myeloid leukemia
  • imatinib
  • molecular response
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cortes, J., Quintás-Cardama, A., & Kantarjian, H. M. (2011). Monitoring molecular response in chronic myeloid leukemia. Cancer, 117(6), 1113-1122. https://doi.org/10.1002/cncr.25527

Monitoring molecular response in chronic myeloid leukemia. / Cortes, Jorge; Quintás-Cardama, Alfonso; Kantarjian, Hagop M.

In: Cancer, Vol. 117, No. 6, 15.03.2011, p. 1113-1122.

Research output: Contribution to journalReview article

Cortes, J, Quintás-Cardama, A & Kantarjian, HM 2011, 'Monitoring molecular response in chronic myeloid leukemia', Cancer, vol. 117, no. 6, pp. 1113-1122. https://doi.org/10.1002/cncr.25527
Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011 Mar 15;117(6):1113-1122. https://doi.org/10.1002/cncr.25527
Cortes, Jorge ; Quintás-Cardama, Alfonso ; Kantarjian, Hagop M. / Monitoring molecular response in chronic myeloid leukemia. In: Cancer. 2011 ; Vol. 117, No. 6. pp. 1113-1122.
@article{7465dc72e4c64fb699ae3cc6f7d10db3,
title = "Monitoring molecular response in chronic myeloid leukemia",
abstract = "Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a reliance on molecular monitoring to assess residual leukemic disease. The prognostic significance between molecular responses and duration of complete cytogenetic response, progression-free survival, and event-free survival is described herein. A discussion of the concept of complete molecular response is also provided, and the potential for imatinib treatment discontinuation is evaluated. The implications of rising BCR-ABL1 transcript levels and caveats of molecular monitoring are also described.",
keywords = "BCR-ABL, chronic myeloid leukemia, imatinib, molecular response, tyrosine kinase inhibitor",
author = "Jorge Cortes and Alfonso Quint{\'a}s-Cardama and Kantarjian, {Hagop M.}",
year = "2011",
month = "3",
day = "15",
doi = "10.1002/cncr.25527",
language = "English (US)",
volume = "117",
pages = "1113--1122",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Monitoring molecular response in chronic myeloid leukemia

AU - Cortes, Jorge

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop M.

PY - 2011/3/15

Y1 - 2011/3/15

N2 - Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a reliance on molecular monitoring to assess residual leukemic disease. The prognostic significance between molecular responses and duration of complete cytogenetic response, progression-free survival, and event-free survival is described herein. A discussion of the concept of complete molecular response is also provided, and the potential for imatinib treatment discontinuation is evaluated. The implications of rising BCR-ABL1 transcript levels and caveats of molecular monitoring are also described.

AB - Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a reliance on molecular monitoring to assess residual leukemic disease. The prognostic significance between molecular responses and duration of complete cytogenetic response, progression-free survival, and event-free survival is described herein. A discussion of the concept of complete molecular response is also provided, and the potential for imatinib treatment discontinuation is evaluated. The implications of rising BCR-ABL1 transcript levels and caveats of molecular monitoring are also described.

KW - BCR-ABL

KW - chronic myeloid leukemia

KW - imatinib

KW - molecular response

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79952381341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952381341&partnerID=8YFLogxK

U2 - 10.1002/cncr.25527

DO - 10.1002/cncr.25527

M3 - Review article

C2 - 20960522

AN - SCOPUS:79952381341

VL - 117

SP - 1113

EP - 1122

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -